Andres F.  Diaz

Lead Developer, Molecular Biology Specialist | MD/PhD Candidate, University of Arizona COM, Tuscon

Team

  • Andres Diaz (above)
  • Thomas Larsen, PhD (University of Arizona College of Medicine – Tucson)
    Prototype Development Lead, Biomedical Engineer Advisor
  • Anish Vaddireddy, BS (Deloitte, New York, NY)
    Data Scientist Lead, App Development
  • Sohail Daulat, BS (University of Pittsburgh, Pittsburgh, PA)
    Marketing & Biotech Lead, Second App Developer

Summary | EzMTX

High-dose methotrexate (HDMTX) is a key treatment for pediatric malignancies. However, in low-resource settings, clinicians face challenges due to the lack of accessible MTX monitoring tools, making it difficult to track toxicities and optimize treatment. To address this, we designed a low-cost, portable assay for urine-based MTX monitoring: the EzMTX assay. We leverage MTX’s inhibition of dihydrofolate reductase to produce a simple, clinically relevant readout, then integrate this with a digital app that quantifies results for clinical use. Our assay empowers safer and effective HDMTX treatment and supports equitable global pediatric cancer care.

Back to the Innovation Festival